Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication

Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H....

Full description

Saved in:
Bibliographic Details
Published inAlimentary pharmacology & therapeutics Vol. 16; no. 3; pp. 527 - 532
Main Authors Di Caro, S., Ojetti, V., Zocco, M. A., Cremonini, F., Bartolozzi, F., Candelli, M., Lupascu, A., Nista, E. C., Cammarota, G., Gasbarrini, A.
Format Journal Article
LanguageEnglish
Published Oxford UK Blackwell Science Ltd 01.03.2002
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H. pylori‐positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention‐to‐treat and per protocol analyses were performed. Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Conclusions: Mono and dual moxifloxacin‐based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin‐based triple therapy may be considered as a new, effective, first‐line therapy option.
ISSN:0269-2813
1365-2036
DOI:10.1046/j.1365-2036.2002.01165.x